HLA-F expression is a prognostic factor in patients with non-small-cell lung cancer

Lung Cancer

Volumn 74, Issue 3, 2011, Pages 504-509

  Lin, Aifen ^a   Zhang, Xia ^a   Ruan, Yan Yun ^a   Wang, Qing ^a   Zhou, Wen Jun ^a   Yan, Wei Hua ^a  

^a TAIZHOU HOSPITAL OF ZHEJIANG PROVINCE   (China)

Author keywords

HLA F; Non small cell lung cancer; Prognosis

Indexed keywords

HLA F ANTIGEN;

ADULT; AGE; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENDER; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TUMOR DIFFERENTIATION; WESTERN BLOTTING;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 80755153769     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.04.006     Document Type: Article

References (33)

1. Ostrand-Rosenberg S. Immune surveillance: a balance between protumor and antitumor immunity. Curr Opin Genet Dev 2008, 18:11-18.
2. Smyth M.J., Dunn G.P., Schreiber R.D. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006, 90:1-50.
3. Campoli M., Ferrone S. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 2008, 27:5869-5885.
4. Chang C.C., Campoli M., Ferrone S. HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis?. Curr Opin Immunol 2004, 16:644-650.
5. Wischhusen J., Waschbisch A., Wiendl H. Immune-refractory cancers and their little helpers - an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E?. Semin Cancer Biol 2007, 17:459-468.
6. Yan W.H. HLA-G expression in hematologic malignancies. Expert Rev Hematol 2010, 3:67-80.
7. O'Callaghan C.A., Bell J.I. Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. Immunol Rev 1998, 163:129-138.
8. Braud V.M., Allan D.S., McMichael A.J. Functions of nonclassical MHC and non-MHC-encoded class I molecules. Curr Opin Immunol 1999, 11:100-108.
9. Pietra G., Romagnani C., Moretta L., Mingari M.C. HLA-E and HLA-E-bound peptides: recognition by subsets of NK and T cells. Curr Pharm Des 2009, 15:3336-3344.
10. Diehl M., Münz C., Keilholz W., Stevanović S., Holmes N., Loke Y.W., et al. Nonclassical HLA-G molecules are classical peptide presenters. Curr Biol 1996, 6:305-314.
11. Wainwright S.D., Biro P.A., Holmes C.H. HLA-F is a predominantly empty, intracellular TAP-associated MHC class Ib protein with a restricted expression pattern. J Immunol 2000, 164:319-328.
12. Goodridge J.P., Burian A., Lee N., Geraghty D.E. HLA-F complex without peptide binds to MHC class I protein in the open conformer form. J Immunol 2010, 184:6199-6208.
13. Larsen M.H., Hviid T.V. Human leukocyte antigen-G polymorphism in relation to expression, function, and disease. Hum Immunol 2009, 70:1026-1034.
14. Hunt J.S. Stranger in a strange land. Immunol Rev 2006, 213:36-47.
15. Carosella E.D., HoWangYin K.Y., Favier B., LeMaoult J. HLA-G-dependent suppressor cells: diverse by nature, function, and significance. Hum Immunol 2008, 69:700-707.
16. Marín R., Ruiz-Cabello F., Pedrinaci S., Méndez R., Jiménez P., Geraghty D.E., et al. Analysis of HLA-E expression in human tumors. Immunogenetics 2003, 54:767-775.
17. Malmberg K.J., Levitsky V., Norell H., de Matos C.T., Carlsten M., Schedvins K., et al. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Invest 2002, 110:1515-1523.
18. Wischhusen J., Friese M.A., Mittelbronn M., Meyermann R., Weller M. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. J Neuropathol Exp Neurol 2005, 64:523-528.
19. Bianchini M., Levy E., Zucchini C., Pinski V., Macagno C., De Sanctis P., et al. Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. Int J Oncol 2006, 29:83-94.
20. Derré L., Corvaisier M., Charreau B., Moreau A., Godefroy E., Moreau-Aubry A., et al. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J Immunol 2006, 177:3100-3107.
21. Pietra G., Romagnani C., Manzini C., Moretta L., Mingari M.C. The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors. J Biomed Biotechnol 2010, doi:10. 1155/2010/907092.
22. de Kruijf E.M., Sajet A., van Nes J.G., Natanov R., Putter H., Smit V.T., et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol 2010, doi:10. 4049/jimmunol.1002629.
23. Ishitani A., Sageshima N., Lee N., Dorofeeva N., Hatake K., Marquardt H., et al. Protein expression and peptide binding suggest unique and interacting functional roles for HLA-E F, and G in maternal-placental immune recognition. J Immunol 2003, 171:1376-1384.
24. Lee N., Ishitani A., Geraghty D.E. HLA-F is a surface marker on activated lymphocytes. Eur J Immunol 2010, 40:2308-2318.
25. Lee N., Geraghty D.E. HLA-F surface expression on B cell monocyte cell lines is partially independent from tapasin completely independent from TAP. J Immunol 2003, 171:5264-5271.
26. Lepin E.J., Bastin J.M., Allan D.S., Roncador G., Braud V.M., Mason D.Y., et al. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol 2000, 30:3552-3561.
27. Noguchi K., Isogai M., Kuwada E., Noguchi A., Goto S., Egawa K. Detection of anti-HLA-F antibodies in sera from cancer patients. Anticancer Res 2004, 24:3387-3392.
28. Travis W.D., Colby T.V., Corrin B., Shimosato Y., Brambilla E. Collaboration with Sobin LH and pathologists from 14 countries World Health Organization International Histological Classification of Tumours. histological typing of lung and pleural tumours 1999, Springer-Verlag. 3rd ed.
29. International Union Against Cancer (UICC) TNM classification of malignant tumors 2002, 81-83. Wiley-Liss, New York, NY. 6th ed. L.H. Sobin, C. Wittekind (Eds.).
30. Geraghty D.E., Wei X.H., Orr H.T., Koller B.H. Human leukocyte antigen F (HLA-F) An expressed HLA gene composed of a class I coding sequence linked to a novel transcribed repetitive element. J Exp Med 1990, 171:1-18.
31. Lury D., Epstein H., Holmes N. The human class I MHC gene HLA-F is expressed in lymphocytes. Int Immunol 1990, 2:531-537.
32. Boyle L.H., Gillingham A.K., Munro S., Trowsdale J. Selective export of HLA-F by its cytoplasmic tail. J Immunol 2006, 176:6464-6472.
33. Tse K.P., Su W.H., Chang K.P., Tsang N.M., Yu C.J., Tang P., See L.C., et al. Genome-wide association study reveals multiple nasopharyngeal carcinoma-associated loci within the HLA region at chromosome 6p21.3. Am J Hum Genet 2009, 85:194-203.